The Safety and Efficacy of ALLERVAX CAT in Cat Allergic Patients
Open Access
- 1 December 1999
- journal article
- clinical trial
- Published by Elsevier in Clinical Immunology
- Vol. 93 (3) , 222-231
- https://doi.org/10.1006/clim.1999.4795
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats☆☆☆★★★Journal of Allergy and Clinical Immunology, 1998
- Effects of peptide therapy on ex vivo T-cell responsesJournal of Allergy and Clinical Immunology, 1998
- Treatment of cat allergy with T-cell reactive peptides.American Journal of Respiratory and Critical Care Medicine, 1996
- Definition of the human T-cell epitopes of Fel d 1, the major allergen of the domestic catJournal of Allergy and Clinical Immunology, 1996
- Specific immunotherapy in asthma: Is it effective?Journal of Allergy and Clinical Immunology, 1994
- Native and recombinant Fel dI as probes into the relationship of allergen structure to human IgE immunoreactivityMolecular Immunology, 1993
- Immunotherapy for cat asthmaJournal of Allergy and Clinical Immunology, 1988
- The prevalence of allergic skin test reactivity to eight common aeroallergens in the U.S. population: Results from the second National Health and Nutrition Examination SurveyJournal of Allergy and Clinical Immunology, 1987
- The prevalence of indoor allergens in the Baltimore area: House dust-mite and animal-dander antigens measured by immunochemical techniquesJournal of Allergy and Clinical Immunology, 1987
- Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of in vivo and in vitro responsesJournal of Allergy and Clinical Immunology, 1984